The approval is supported by data from the phase 3 LITESPARK-011 trial.
|Articles|June 1, 2003
Watch for these tax evasion schemes-the IRS is
Employment tax evasion can take a variety of forms, and the IRS is watchingfor themAlthough August is when the Internal Revenue Service traditionally beginsselecting those 2002 tax returns that are to be examined in greater depth,many physicians found themselves being targeted for examination soon afterthe April 15 tax deadline. After all, April 15 was also the deadline forparticipating in the IRS's "Offshore Voluntary Compliance Initiative"(OVCI)-a "come back into the fold and you will be forgiven your taxtransgressions" program.
Advertisement
Advertisement
Related to this article
Pearls & Perspectives: Expanding Sexual Health Conversations Through Digital Media, With Wendy Brant
Amy Pearlman, MD, and Wendy Brant discuss building a digital audience, navigating sexual health content online, and the role of communication in relationships.
Positive safety and efficacy data from 4 clinical studies supported the CE marking.
Sandip Prasad, MD, discusses patient selection for chemoablation in recurrent LG-IR-NMIBC and considerations when counseling patients about a nonsurgical approach.
In a head-to-head RCT, Rezūm produced a 4.6-point greater IPSS improvement than combination pharmacotherapy at 1 year, according to Jean-Nicolas Cornu, MD, PhD, FEBU.
The AACU and the WOCN Society urge CMS to protect access to individualized catheter and ostomy supplies as competitive bidding begins in 2028.
Better detection has changed prostate cancer care. Patients choosing radical treatment still need better protection from the disease returning.
Enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) showed the strongest EFS, OS, and PCR associations among neoadjuvant MIBC strategies in a network meta-analysis, although perioperative design limits attribution.
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves belzutifan plus lenvatinib for advanced clear cell renal cell carcinoma
2
After curative-intent treatment, prostate cancer recurrence is still an unmet need
3
Sandip Prasad, MD, on patient selection for chemoablation in LG-IR-NMIBC
4
FemPulse Ring receives EU approval for overactive bladder
5